Deficiency of coagulation factor IX will result in Hemophilia B disorder. Treatment of Hemophilia B has been evolved with the introduction of first of plasma-derived and then of recombinant FIX concentrates. Prevalence of Hemophilia B is anticipated to be 1 in 30,000 individuals across the globe, which is likely to bolster significant demand for coagulation factor IX over foreseeable future.
Incidences of hemophilia B have not been well known however, over 40 thousand people are ... Read more